ALNYLAM PHARMACEUTICALS INC (DUL.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:DUL • US02043Q1076
DUL.DE Key Statistics, Chart & Performance
The current stock price of DUL.DE is 287.6 EUR. In the past month the price decreased by -13.76%.
DUL.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DUL.DE.
DUL.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to DUL.DE. Both the profitability and the financial health of DUL.DE get a neutral evaluation. Nothing too spectacular is happening here.
DUL.DE Financial Highlights
Over the last trailing twelve months DUL.DE reported a non-GAAP Earnings per Share(EPS) of 0.43. The EPS increased by 119.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.36% | ||
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| Debt/Equity | 10.22 |
DUL.DE Forecast & Estimates
36 analysts have analysed DUL.DE and the average price target is 441.79 EUR. This implies a price increase of 53.61% is expected in the next year compared to the current price of 287.6.
For the next year, analysts expect an EPS growth of 209.79% and a revenue growth 68% for DUL.DE
DUL.DE Ownership
DUL.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 68 | 44.18B | ||
| ARGX.BR | ARGENX SE | 68.44 | 44.47B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.09B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.53B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.91B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.90B | ||
| IVA.PA | INVENTIVA SA | N/A | 1.01B | ||
| 6IV.DE | INVENTIVA SA | N/A | 953.87M | ||
| NANO.PA | NANOBIOTIX | N/A | 878.72M | ||
| PHIL.MI | PHILOGEN SPA | 18.9 | 630.12M | ||
| FYB.DE | FORMYCON AG | N/A | 410.83M |
Related stock screener links
About DUL.DE
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Company Info
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS US
Employees: 2230
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / DUL.DE FAQ
Can you describe the business of ALNYLAM PHARMACEUTICALS INC?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
What is the stock price of ALNYLAM PHARMACEUTICALS INC today?
The current stock price of DUL.DE is 287.6 EUR. The price decreased by -1.37% in the last trading session.
Does DUL stock pay dividends?
DUL.DE does not pay a dividend.
How is the ChartMill rating for ALNYLAM PHARMACEUTICALS INC?
DUL.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
On which exchange is DUL.DE stock listed?
DUL.DE stock is listed on the Frankfurt Stock Exchange exchange.
Is ALNYLAM PHARMACEUTICALS INC (DUL.DE) expected to grow?
The Revenue of ALNYLAM PHARMACEUTICALS INC (DUL.DE) is expected to grow by 68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns ALNYLAM PHARMACEUTICALS INC?
You can find the ownership structure of ALNYLAM PHARMACEUTICALS INC (DUL.DE) on the Ownership tab.